Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Therapeutic Effects and Mechanism of Liraglutide in Rats with Type 2 Diabetes and Metabolic-associated Fatty Liver Disease

Author(s): Xuanye Zhao, Yaoji Liu, Jingjin Liu and jie Qin*

Volume 22, Issue 9, 2022

Published on: 06 June, 2022

Page: [963 - 969] Pages: 7

DOI: 10.2174/1871530322666220126151141

Price: $65

Abstract

Background: SREBP-1c/Insig/SCAP acts as a lipid de novo synthesis pathway, and its factors are highly expressed in the endoplasmic reticulum. At present, this pathway has become a research hotspot in the development of metabolic-associated fatty liver disease. However, there are few studies on how various factors in this pathway change after endoplasmic reticulum stress; in particular, the role of the insulin-inducing gene-1 (Insig-1) has not been elucidated in detail.

Objective: The aim of the study was to investigate whether liraglutide has a therapeutic effect on rats with T2DM and MAFLD, and to further study its possible mechanism.

Methods: Rats in the control group and modeling group were fed with normal diet and high-sugar and high-fat diet, respectively. After one month, the mice in the modeling group were injected with 35mg/kg STZ intraperitoneally to establish the model of type 2 diabetes mellitus. T2DM and MAFLD rats were randomly divided into three groups: model group, low-dose liraglutide group, and high-dose liraglutide group. Fasting blood glucose, fasting insulin, blood lipid profile, alanine aminotransferase, and aspartate aminotransferase were measured at the end of 8th week. Paraffin sections were obtained from the same part of the liver of rats in each group and observed by electron microscope after HE staining. Western blot was used to detect the expression of endoplasmic reticulum stress index (GRP78) and negative feedback index of lipid synthesis (Insig-1) in each group.

Results: Liver tissue from the drug intervention groups demonstrated a decrease in lipid droplet vacuoles, and the hepatocytes were arranged neatly again. While the expression of GRP78 rose, that of Insig-1 declined. There were differences observed with different doses of liraglutide; the higher the dose was, the more obvious the effect. No such changes were observed in T2DM and MAFLD rats after injection of saline.

Conclusion: In this study, we show that liraglutide may have a therapeutic effect on rats with T2DM and MAFLD by reducing endoplasmic reticulum stress in the liver and increasing the expression of Insig-1.

Keywords: Type 2 diabetes mellitus (T2DM), metabolism-related fatty liver disease- MAFLD, liraglutide, endoplasmic reticulum stress, insulin inducible gene-1, GRP78.

« Previous Next »
Graphical Abstract

[1]
Mukherjee, A.; Morales-Scheihing, D.; Butler, P.C.; Soto, C. Type 2 diabetes as a protein misfolding disease. Trends Mol. Med., 2015, 21(7), 439-449.
[http://dx.doi.org/10.1016/j.molmed.2015.04.005] [PMID: 25998900]
[2]
Eslam, M.; Sanyal, A.J.; George, J. International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 2020, 158(7), 1999-2014.e1.
[http://dx.doi.org/10.1053/j.gastro.2019.11.312] [PMID: 32044314]
[3]
Zelber-Sagi, S.; Schonmann, Y.; Yeshua, H.; Bentov, I. Reply to: “Assessment of hepatic fibrosis in MAFLD: a new player in the evaluation of residual cardiovascular risk?”. Dig. Liver Dis., 2021, 53(3), 385-386.
[http://dx.doi.org/10.1016/j.dld.2021.01.014] [PMID: 33509738]
[4]
Boden, G. Obesity, insulin resistance and free fatty acids. Curr. Opin. Endocrinol. Diabetes Obes., 2011, 18(2), 139-143.
[http://dx.doi.org/10.1097/MED.0b013e3283444b09] [PMID: 21297467]
[5]
Eslam, M.; Newsome, P.N.; Sarin, S.K.; Anstee, Q.M.; Targher, G.; Romero-Gomez, M.; Zelber-Sagi, S.; Wai-Sun Wong, V.; Dufour, J.F.; Schattenberg, J.M.; Kawaguchi, T.; Arrese, M.; Valenti, L.; Shiha, G.; Tiribelli, C.; Yki-Järvinen, H.; Fan, J.G.; Grønbæk, H.; Yilmaz, Y.; Cortez-Pinto, H.; Oliveira, C.P.; Bedossa, P.; Adams, L.A.; Zheng, M.H.; Fouad, Y.; Chan, W.K.; Mendez-Sanchez, N.; Ahn, S.H.; Castera, L.; Bugianesi, E.; Ratziu, V.; George, J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol., 2020, 73(1), 202-209.
[http://dx.doi.org/10.1016/j.jhep.2020.03.039] [PMID: 32278004]
[6]
Qi, L.; Tian, Y.; Chen, Y. Circulating bile acid profiles: A need for further examination. J. Clin. Endocrinol. Metab., 2021, 106(11), 3093-3112.
[http://dx.doi.org/10.1210/clinem/dgab531] [PMID: 34279029]
[7]
Różański, G.; Kujawski, S.; Newton, J.L.; Zalewski, P.; Słomko, J. Curcumin and biochemical parameters in metabolic-associated fatty liver disease (MAFLD)-a review. Nutrients, 2021, 13(8), 2654.
[http://dx.doi.org/10.3390/nu13082654] [PMID: 34444811]
[8]
Ao, N.; Yang, J.; Wang, X.; Du, J. Glucagon-like peptide-1 preserves non-alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress-associated pathway. Hepatol. Res., 2016, 46(4), 343-353.
[http://dx.doi.org/10.1111/hepr.12551] [PMID: 26147696]
[9]
Ouyang, S.; Mo, Z.; Sun, S.; Yin, K.; Lv, Y. Emerging role of Insig-1 in lipid metabolism and lipid disorders. Clin. Chim. Acta, 2020, 508, 206-212.
[http://dx.doi.org/10.1016/j.cca.2020.05.042] [PMID: 32461046]
[10]
Huang, S.; Zhu, M.; Wu, W.; Rashid, A.; Liang, Y.; Hou, L. Valproate pretreatment protects pancreatic β-cells from palmitate-induced ER stress and apoptosis by inhibiting glycogen synthase kinase-3β. J. Biomed. Sci., 2014, 21, 21-38.
[http://dx.doi.org/10.1186/1423-0127-21-38]
[11]
Moon, Y.A.; Liang, G.; Xie, X.; Frank-Kamenetsky, M.; Fitzgerald, K.; Koteliansky, V.; Brown, M.S.; Goldstein, J.L.; Horton, J.D. The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab., 2012, 15(2), 240-246.
[http://dx.doi.org/10.1016/j.cmet.2011.12.017] [PMID: 22326225]
[12]
Lee, J.N.; Ye, J. Proteolytic activation of sterol regulatory element-binding protein induced by cellular stress through depletion of Insig-1. J. Biol. Chem., 2004, 279(43), 45257-45265.
[http://dx.doi.org/10.1074/jbc.M408235200] [PMID: 15304479]
[13]
Engelking, L.J.; Kuriyama, H.; Hammer, R.E.; Horton, J.D.; Brown, M.S.; Goldstein, J.L.; Liang, G. Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. J. Clin. Invest., 2004, 113(8), 1168-1175.
[http://dx.doi.org/10.1172/JCI20978] [PMID: 15085196]
[14]
Mundil, D.; Cameron-Vendrig, A.; Husain, M. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab. Vasc. Dis. Res., 2012, 9(2), 95-108.
[http://dx.doi.org/10.1177/1479164112441526] [PMID: 22496442]
[15]
Robinson, L.E.; Holt, T.A.; Rees, K.; Randeva, H.S.; O’Hare, J.P. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open, 2013, 3(1), e001986.
[http://dx.doi.org/10.1136/bmjopen-2012-001986] [PMID: 23355666]
[16]
Altaf, Q.A.; Barnett, A.H.; Tahrani, A.A. Novel therapeutics for type 2 diabetes: insulin resistance. Diabetes Obes. Metab., 2015, 17(4), 319-334.
[http://dx.doi.org/10.1111/dom.12400] [PMID: 25308775]
[17]
Eguchi, Y.; Kitajima, Y.; Hyogo, H.; Takahashi, H.; Kojima, M.; Ono, M.; Araki, N.; Tanaka, K.; Yamaguchi, M.; Matsuda, Y.; Ide, Y.; Otsuka, T.; Ozaki, I.; Ono, N.; Eguchi, T.; Anzai, K. Japan Study Group for NAFLD (JSG-NAFLD). Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol. Res., 2015, 45(3), 269-278.
[http://dx.doi.org/10.1111/hepr.12351] [PMID: 24796231]
[18]
Liu, J.; Wang, G.; Jia, Y.; Xu, Y. GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease. Diabetes Metab. Res. Rev., 2015, 31(4), 329-335.
[http://dx.doi.org/10.1002/dmrr.2580] [PMID: 25066109]
[19]
Dai, Y.; He, H.; Li, S.; Yang, L.; Wang, X.; Liu, Z. Comparison of the efficacy of glucagon-like peptide-1 receptor agonists in patients with metabolic associated fatty liver disease: Updated systematic review and meta-analysis. Front. Endocrinol. (Lausanne), 2021, 11, 622589.

Rights & Permissions Print Cite
Article Metrics
16
1
© 2024 Bentham Science Publishers | Privacy Policy